Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Other Non-current Assets

Long-term assets not reported separately.

Cabaletta Bio, Inc.NASDAQ: CABA

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets rises 122.6% from a year ago

Other non-current assets stood at $5.27M at the end of Q1 FY2026, up 122.6% from a year earlier and up 2.2% from the prior quarter. Over 3 fiscal years it compounded at +109.0% a year.

Context

  • Other non-current assets amounted to 3.6% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
  • Other non-current assets increased in 2 of the last 3 fiscal years.

What to watch

Whether other non-current assets keeps rising in the next quarterly balance sheet after a +122.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.27M+2.2% QoQ
Last fiscal yearDec 2025
$5.16M-17.2% YoY
Year agoMar 2025
$2.37M+122.6% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+122.6%——
1 year-17.2%——
3-year CAGR+109.0%——
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
5.16M USD
Year-over-year change
-17.2%
4-year CAGR
+95.0%

Other Non-current Assets vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +122.6% is the 3rd highest of 10, against a peer median of +30.5%.
  • Other non-current assets amounts to 3.6% of total assets for CABA, versus a peer median of 0.7%.
CABA Competitors
Other Non-current Assets for CABA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LYELLyell Immunopharma, Inc.Mar 2026$13.77M USD+180.8%+9.3%3.9%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$6.64M USD+104.4%-24.3%2.7%
KYTXKyverna Therapeutics, Inc.Mar 2026$5.57M USD+32.5%+64.2%2.2%
CABACabaletta Bio, Inc.Mar 2026$5.27M USD+122.6%+109.0%3.6%
ALLOAllogene Therapeutics, Inc.Mar 2026$3.53M USD-89.6%+23.5%0.9%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$3.05M USD-30.6%+28.0%1.1%
CAPRCapricor Therapeutics, Inc.Mar 2026$1.53M USD+505.3%+279.8%0.5%
HUMAHumacyte, Inc.Mar 2026$672K USD-98.7%—0.6%
EDITEditas Medicine, Inc.Mar 2026$306K USD-4.7%-62.5%0.2%
IMMPImmutep LimitedDec 2025A$141.77K AUD+30.5%-38.3%0.1%
PRQRProQR Therapeutics N.V.Mar 2026€0 EUR——0.0%
Peer median (excluding CABA) —+30.5%+16.4%0.7%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.22M81.61M193.24M163.96M82.98M
Short-term Investments024.94M48.01M050.62M
Net Receivables00000
Inventory00000
Other Current Assets1.97M2.29M02.71M5.27M
Total Current Assets124.54M108.83M244.49M166.68M138.87M
Property, Plant & Equipment (Net)1.44M7.57M7.45M16.08M21.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets357K565K1.71M6.23M5.16M
Total Non-current Assets1.8M8.13M9.16M22.31M26.21M
Total Assets126.34M116.97M253.65M185.05M165.08M
Account Payables2.33M2.46M4.55M4.92M6.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.07M1.33M40K8.36M9.8M
Total Current Liabilities8.38M9.49M15.99M27.09M50.15M
Long-term Debt00002.88M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities02.96M1.46M5.63M2.88M
Total Liabilities8.38M12.45M17.45M32.71M53.03M
Common Stock0001K1K
Retained Earnings(112.59M)(165.56M)(233.24M)(349.1M)(516.96M)
Accumulated OCI0(47K)39K025K
Other Stockholders Equity00000
Minority Interest00000
Total Equity117.96M104.52M236.2M152.34M112.05M
Total Debt05.14M5.02M15.6M27.1M
Net Debt(122.22M)(76.47M)(188.22M)(148.36M)(55.88M)

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.